Frequent emergence of n348i in hiv-1 subtype c reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors

Clinical Infectious Diseases

Volumn 55, Issue 5, 2012, Pages 737-745

  Brehm, Jessica H ^a   Koontz, Dianna L ^a   Wallis, Carole L ^b   Shutt, Kathleen A ^a   Sanne, Ian ^b   Wood, Robin ^e   McIntyre, James A ^c   Stevens, Wendy S ^b,d   Sluis Cremer, Nicolas ^a   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c ANOVA HEALTH INSTITUTE   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL TRIAL; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SEQUENCE; VIRUS GENE;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84864944623     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis501     Document Type: Article

References (40)

1. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-4.
2. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-31.
3. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97.
4. Wang J, Smerdon SJ, Jager J, et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci U S A 1994; 91:7242-6.
5. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4:e335.
6. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82:3261-70.
7. Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob Agents Chemother 2010; 54:1973-80.
8. Hachiya A, Shimane K, Sarafianos SG, et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatmentnaive patients. Antiviral Res 2009; 82:115-21.
9. McCormick AL, Parry CM, Crombe A, et al. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob Agents Chemother 2011; 55:1806-9.
10. Price H, Asboe D, Pozniak A, et al. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir Ther 2010; 15:203-11.
11. von Wyl V, Ehteshami M, Demeter LM, et al. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis 2010; 51:620-8.
12. Waters JM, O'Neal W, White KL, et al. Mutations in the thumbconnection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir Ther 2009; 14:231-9.
13. Biondi MJ, Beilhartz GL, McCormick S, Gotte M. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation. J Biol Chem 2010; 285:26966-75.
14. Ehteshami M, Beilhartz GL, Scarth BJ, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3?-azido-3?-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008; 283:22222-32.
15. Schuckmann MM, Marchand B, Hachiya A, et al. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. J Biol Chem 2010; 285:38700-9.
16. von Wyl V, Ehteshami M, Symons J, et al. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis 2010; 201:1054-62.
17. Sluis-Cremer N, Moore K, Radzio J, Sonza S, Tachedjian G. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. AIDS 2010; 24:317-9.
18. Gupta S, Vingerhoets J, Fransen S, et al. Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob Agents Chemother 2011; 55:2872-9.
19. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
20. Grossman Z, Istomin V, Averbuch D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV- 1 subtype C. AIDS 2004; 18:909-15.
21. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-5.
22. Roquebert B, Wirden M, Simon A, et al. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J Med Virol 2007; 79:207-11.
23. Saeng-aroon S, Tsuchiya N, Auwanit W, et al. Drug-resistant mutation patterns in CRF01-AE cases that failed d4T+3TC + nevirapine fixeddosed, combination treatment: follow-up study from the Lampang cohort. Antiviral Res 2010; 87:22-9.
24. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010; 376:33-40.
25. Los Alamos HIV Sequence Database. Available at: http://www. hiv. lanl. gov/. Accessed 18 March 2010.
26. Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2. 0. Bioinformatics 2007; 23:2947-8.
27. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
28. Abecasis AB, Wang Y, Libin P, et al. Comparative performance of the REGA subtyping tool version 2 versus version 1. Infect Genet Evol 10:380-5.
29. Brehm JH, Scott Y, Koontz DL, et al. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. PLoS One 2012; 7:e31558.
30. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005; 49:1139-44.
31. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27:493-7.
32. Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19:156-64.
33. Wallis CL, Papathanasopolous MA, Fox M, et al. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther 2012; 17:313-20.
34. Menendez-Arias L, Betancor G, Matamoros T. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Res 2011; 92:139-49.
35. Delviks-Frankenberry KA, Nikolenko GN, Pathak VK. The "connection" between HIV drug resistance and RNase H. Viruses 2010; 2:1476-503.
36. Ehteshami M, Gotte M. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 2008; 10:224-35.
37. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel nextgeneration nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-6.
38. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503-14.
39. Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. AIDS 2010; 24:659-67.
40. Brehm JH, Lalama CM, Hughes MD, et al. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. J Acquir Immune Defic Syndr 2011; 56:344-8.